Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2017

Anders Nygren's Biography



Anders Nygren, Senior Director, Research and Development, Agena Biosciences

Dr. Nygren serves as the Senior Director, Research and Development at Agena Biosciences located in San Diego, USA. He joined Agena Bioscience, formerly Sequenom in 2008, serving in various roles within the R&D department. Since joining Agena Biosciences Dr Nygren has focused of on different aspects of nucleic acid analysis with emphasis on ultrasensitive detection of somatic mutations isolated from tumor and circulating cell free DNA. Prior to joining Agena/Sequenom Dr Nygren was part in the commercialization team of the multiplex ligation dependent probe amplification (MLPA) technology for relative quantification of nucleic acid copy numbers and is the inventor of Methylation-Specific MLPA. Dr. Nygren received his Master of Science in Molecular Biotechnology at Uppsala University and his PhD in clinical chemistry at the Free University of Amsterdam.

Anders Nygren Image

Dipping into the Different Aspects of Liquid Biopsy-based DNA Analysis

Thursday, 5 October 2017 at 16:30

Add to Calendar ▼2017-10-05 16:30:002017-10-05 17:30:00Europe/LondonDipping into the Different Aspects of Liquid Biopsy-based DNA AnalysisLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Circulating cell free DNA analysis presents both opportunities and challenges in harnessing the potential of circulating nucleic acid biomarkers. While most efforts have been focused on the ultrasensitive detection of rare somatic mutations very little focus have been spent on other nucleic acid based biomarkers. In my talk, I, will present several highly sensitive novel liquid biopsy based applications. These applications include large multiplex panels able to identify epigenetic aberrations both within the field of non-invasive prenatal testing and detection of circulating tumor DNA. Finally, I will present data on a novel assay able to detect and quantify the mitochondrial dosage and thereby serve as an early liquid biopsy based detection assay for many neurodegenerative diseases.


Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com